Examples of 'telavancin' in a sentence
Meaning of "telavancin"
'Telavancin' as a noun refers to a type of antibiotic used to treat certain infections like skin infections caused by bacteria
Show more definitions
- A bactericidal lipoglycopeptide.
How to use "telavancin" in a sentence
Basic
Advanced
telavancin
Telavancin must not be given to pregnant women.
The macrophages were shown to contain telavancin and.
Telavancin has no effect on platelet aggregation.
It is unknown whether telavancin is excreted in human breast milk.
Telavancin has a small volume of distribution.
There is no human experience with telavancin.
Profile of telavancin when used in the clinical setting.
It contains the active substance telavancin.
Telavancin is a semisynthetic lipoglycopeptide derivative of vancomycin.
This data indicate that telavancin is not extensively distributed.
Coagulation tests unaffected by telavancin.
Typically telavancin is prepared as a hydrochloride salt.
Coagulation tests affected by telavancin.
The excretion of telavancin in milk has not been studied in animals.
Vibativ is a medicine that contains the active substance telavancin.
See also
It is not known if telavancin passes into breast milk in humans.
Patients with these conditions were not included in clinical trials of telavancin.
Telavancin has a higher rate of kidney failure than vancomycin in two clinical trials.
Renal excretion is the major route of elimination for telavancin in humans.
In vitro studies showed that telavancin retained full activity in the presence of pulmonary surfactant.
Fractions were collected until the hydrochloride salt of telavancin was no longer detected.
Telavancin may interfere with some laboratory tests that measure proteins in the urine.
No evidence of increased bleeding risk has been observed in clinical trials with telavancin.
Telavancin may interfere with some laboratory tests that measure how well your blood is clotting.
The studies did not provide any evidence for a genotoxic potential of telavancin.
Telavancin was cleared by CVVH and the clearance of telavancin increased with increasing ultrafiltration rate.
Each fraction was analyzed by thin layer chromatography for the presence of telavancin.
If an allergic reaction to telavancin occurs, discontinue treatment and institute.
Have ever had an allergic reaction to another glycopeptide antibiotic such as vancomycin and telavancin.
No clinically significant gender-related differences in telavancin pharmacokinetics have been observed.
Each fraction was collected and tested for the presence of the hydrochloride salt of telavancin.
If an allergic reaction to telavancin occurs, discontinue treatment and institute appropriate therapy.
Also, the pharmacokinetics of aztreonam or piperacillin tazobactam were not altered by telavancin.
The apparent distribution volume of telavancin at steady-state in healthy adult subjects was.
In healthy young adults, three hydroxylated metabolites were identified after infusion of telavancin.
Therefore, caution should be exercised if telavancin is given to subjects with severe hepatic impairment.
If renal function markedly decreases during treatment, the benefit of continuing telavancin should be assessed.
For example, the hydrochloride salt of telavancin can be precipitated and centrifuged or filtered.
Telavancin has a dual mechanism of antibacterial action, disrupting peptidoglycan synthesis and cell membrane function.
There is no known cross-resistance between telavancin and other non-glycopeptide classes of antibiotics.
Telavancin exerts concentration-dependent bactericidal activity against susceptible Gram-positive bacteria.
After reconstitution, each ml of concentrated solution contains 15 mg of telavancin.
VIBATIV contains telavancin as active substance, which is an antibiotic of the glycopeptide group.
After reconstitution each ml contains 15 mg of telavancin.
Telavancin is approved only to treat S. aureus, not other bacteria that cause pneumonia.
Isolating the hydrochloride salt of telavancin produced in step ( b ).
The pharmacokinetics of telavancin have not been evaluated in severe hepatic impairment Child-Pugh class C.
Treatment was discontinued due to adverse reactions in 5.0 % of patients who received telavancin.
Telavancin exhibited linear pharmacokinetics at doses up to 15 mg / kg administered as a daily.
The apparent distribution volume of telavancin at steady-state in healthy adult subjects was approximately 133 ml / kg.
